SE9801495D0 - Protein formulationa - Google Patents

Protein formulationa

Info

Publication number
SE9801495D0
SE9801495D0 SE9801495A SE9801495A SE9801495D0 SE 9801495 D0 SE9801495 D0 SE 9801495D0 SE 9801495 A SE9801495 A SE 9801495A SE 9801495 A SE9801495 A SE 9801495A SE 9801495 D0 SE9801495 D0 SE 9801495D0
Authority
SE
Sweden
Prior art keywords
protein formulation
pharmaceutical formulations
osteoporosis
useful
concentration
Prior art date
Application number
SE9801495A
Other languages
English (en)
Inventor
Martin Billger
Mikael Bruells
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9801495A priority Critical patent/SE9801495D0/sv
Publication of SE9801495D0 publication Critical patent/SE9801495D0/sv
Priority to AT99917715T priority patent/ATE273693T1/de
Priority to ES99917715T priority patent/ES2224637T3/es
Priority to IL139320A priority patent/IL139320A/en
Priority to NZ508269A priority patent/NZ508269A/en
Priority to EP99917715A priority patent/EP1079803B1/en
Priority to CNB998073628A priority patent/CN1172658C/zh
Priority to PCT/CA1999/000376 priority patent/WO1999055353A2/en
Priority to SI9930678T priority patent/SI1079803T1/xx
Priority to DK99917715T priority patent/DK1079803T3/da
Priority to DE69919533T priority patent/DE69919533T2/de
Priority to KR1020007012037A priority patent/KR100579872B1/ko
Priority to CA002329800A priority patent/CA2329800C/en
Priority to AU35916/99A priority patent/AU766514B2/en
Priority to JP2000545551A priority patent/JP4733267B2/ja
Priority to PT99917715T priority patent/PT1079803E/pt
Priority to DE122006000057C priority patent/DE122006000057I2/de
Priority to DE1999619533 priority patent/DE122006000057I1/de
Priority to BR9909958-6A priority patent/BR9909958A/pt
Priority to ZA200006040A priority patent/ZA200006040B/en
Priority to HK02102980.6A priority patent/HK1041218B/zh
Priority to AU2004200156A priority patent/AU2004200156B2/en
Priority to US10/999,160 priority patent/US20050209144A1/en
Priority to NL300243C priority patent/NL300243I2/nl
Priority to LU91281C priority patent/LU91281I2/fr
Priority to FR06C0032C priority patent/FR06C0032I2/fr
Priority to CY200600006C priority patent/CY2006006I1/el
Priority to JP2011011811A priority patent/JP5753692B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
SE9801495A 1998-04-28 1998-04-28 Protein formulationa SE9801495D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa
BR9909958-6A BR9909958A (pt) 1998-04-28 1999-04-26 Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
CA002329800A CA2329800C (en) 1998-04-28 1999-04-26 Protein formulations
JP2000545551A JP4733267B2 (ja) 1998-04-28 1999-04-26 タンパク質製剤
IL139320A IL139320A (en) 1998-04-28 1999-04-26 Pharmaceutical preparations containing human parathyroid hormone
NZ508269A NZ508269A (en) 1998-04-28 1999-04-26 Protein formulations
EP99917715A EP1079803B1 (en) 1998-04-28 1999-04-26 Protein formulations
CNB998073628A CN1172658C (zh) 1998-04-28 1999-04-26 蛋白质制剂
PCT/CA1999/000376 WO1999055353A2 (en) 1998-04-28 1999-04-26 Protein formulations
SI9930678T SI1079803T1 (en) 1998-04-28 1999-04-26 Protein formulations
DK99917715T DK1079803T3 (da) 1998-04-28 1999-04-26 Proteinholdige præparater
DE69919533T DE69919533T2 (de) 1998-04-28 1999-04-26 Proteinhaltige arzneimittel
KR1020007012037A KR100579872B1 (ko) 1998-04-28 1999-04-26 단백질 제제
AT99917715T ATE273693T1 (de) 1998-04-28 1999-04-26 Proteinhaltige arzneimittel
AU35916/99A AU766514B2 (en) 1998-04-28 1999-04-26 Protein formulations
ES99917715T ES2224637T3 (es) 1998-04-28 1999-04-26 Formulaciones deproteina.
PT99917715T PT1079803E (pt) 1998-04-28 1999-04-26 Formulacoes de proteinas
DE122006000057C DE122006000057I2 (de) 1998-04-28 1999-04-26 Proteinhaltige arzneimittel
DE1999619533 DE122006000057I1 (de) 1998-04-28 1999-04-26 Proteinhaltige Arzneimittel
ZA200006040A ZA200006040B (en) 1998-04-28 2000-10-26 Protein formulations.
HK02102980.6A HK1041218B (zh) 1998-04-28 2002-04-19 蛋白質製劑
AU2004200156A AU2004200156B2 (en) 1998-04-28 2004-01-16 Protein formulations
US10/999,160 US20050209144A1 (en) 1998-04-28 2004-11-30 Protein formulations
NL300243C NL300243I2 (nl) 1998-04-28 2006-10-17 Proteïne formuleringen.
LU91281C LU91281I2 (fr) 1998-04-28 2006-10-19 Preotact-hormone parathyroïde
FR06C0032C FR06C0032I2 (fr) 1998-04-28 2006-10-20 Formulations proteiniques
CY200600006C CY2006006I1 (el) 1998-04-28 2006-10-23 Πρωτεϊνικα σκευασματα
JP2011011811A JP5753692B2 (ja) 1998-04-28 2011-01-24 タンパク質製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa

Publications (1)

Publication Number Publication Date
SE9801495D0 true SE9801495D0 (sv) 1998-04-28

Family

ID=20411122

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa

Country Status (24)

Country Link
US (1) US20050209144A1 (sv)
EP (1) EP1079803B1 (sv)
JP (2) JP4733267B2 (sv)
KR (1) KR100579872B1 (sv)
CN (1) CN1172658C (sv)
AT (1) ATE273693T1 (sv)
AU (2) AU766514B2 (sv)
BR (1) BR9909958A (sv)
CA (1) CA2329800C (sv)
CY (1) CY2006006I1 (sv)
DE (3) DE69919533T2 (sv)
DK (1) DK1079803T3 (sv)
ES (1) ES2224637T3 (sv)
FR (1) FR06C0032I2 (sv)
HK (1) HK1041218B (sv)
IL (1) IL139320A (sv)
LU (1) LU91281I2 (sv)
NL (1) NL300243I2 (sv)
NZ (1) NZ508269A (sv)
PT (1) PT1079803E (sv)
SE (1) SE9801495D0 (sv)
SI (1) SI1079803T1 (sv)
WO (1) WO1999055353A2 (sv)
ZA (1) ZA200006040B (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN104645318B (zh) * 2011-06-07 2021-11-02 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
IL307981A (en) 2015-04-29 2023-12-01 Radius Pharmaceuticals Inc Cancer treatment methods
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN108333360A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 胃泌素释放肽前体稀释液及其应用和试剂盒
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JP2662842B2 (ja) * 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH09157294A (ja) * 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
JP4053107B2 (ja) * 1996-02-01 2008-02-27 中外製薬株式会社 血小板減少症の予防剤および治療剤
US5964807A (en) * 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa

Also Published As

Publication number Publication date
DE69919533T2 (de) 2005-09-08
NL300243I1 (nl) 2006-12-01
AU766514B2 (en) 2003-10-16
ZA200006040B (en) 2002-01-28
AU2004200156A1 (en) 2004-02-12
FR06C0032I2 (fr) 2007-04-27
CY2006006I2 (el) 2009-11-04
CN1319003A (zh) 2001-10-24
DE69919533D1 (de) 2004-09-23
HK1041218B (zh) 2005-03-18
KR20010052276A (ko) 2001-06-25
CA2329800A1 (en) 1999-11-04
JP4733267B2 (ja) 2011-07-27
CN1172658C (zh) 2004-10-27
DE122006000057I1 (de) 2007-01-04
JP2002512973A (ja) 2002-05-08
CA2329800C (en) 2004-06-15
JP2011105739A (ja) 2011-06-02
ES2224637T3 (es) 2005-03-01
CY2006006I1 (el) 2009-11-04
KR100579872B1 (ko) 2006-05-12
DK1079803T3 (da) 2004-11-22
IL139320A0 (en) 2001-11-25
IL139320A (en) 2007-06-17
EP1079803B1 (en) 2004-08-18
EP1079803A2 (en) 2001-03-07
JP5753692B2 (ja) 2015-07-22
US20050209144A1 (en) 2005-09-22
AU3591699A (en) 1999-11-16
WO1999055353A3 (en) 2000-01-13
SI1079803T1 (en) 2005-02-28
FR06C0032I1 (sv) 2006-11-24
ATE273693T1 (de) 2004-09-15
HK1041218A1 (en) 2002-07-05
BR9909958A (pt) 2000-12-26
LU91281I2 (fr) 2006-12-19
AU2004200156B2 (en) 2005-12-15
NZ508269A (en) 2003-12-19
WO1999055353A2 (en) 1999-11-04
DE122006000057I2 (de) 2009-11-05
PT1079803E (pt) 2004-11-30
NL300243I2 (nl) 2007-02-01

Similar Documents

Publication Publication Date Title
FR06C0032I2 (fr) Formulations proteiniques
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
BR0008059A (pt) Composições de valdecoxib
YU7797A (sh) Kombinovana terapija za osteoporozu
PT994710E (pt) Composicoes farmaceuticas administraveis por via oral incluindo uma benzidrilpiperazina e uma ciclodextrina
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
UY27373A1 (es) Formulaciones de interferón beta-humano
PT917460E (pt) Formulacoes de ciclosporina
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BR0011845A (pt) Complexo farmacêutico
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
HUP0100634A2 (hu) Pentaeritrit-tetranitrátot tartalmazó gyógyászati készítmények
IT1307866B1 (it) Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento
ATE262538T1 (de) Lhrh-analoga zur behandlung der osteoporose
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio